AFT Pharmaceuticals’ shares fall as drug fails FDA threshold

AFT Pharmaceuticals’ shares fall as drug fails FDA threshold
AFT Pharmaceuticals managing director Hartley Atkinson still believes Pascomer shows promise. (Image: AFT Pharmaceuticals)
Riley Kennedy
AFT Pharmaceuticals’ shares have fallen this morning after the company said a drug it is developing to treat facial angiofibromas (FA) had failed to reach the threshold for US Food and Drug Administration (FDA) registration.The company’s shares declined 3.3% to $3.80 in morning trading, after the pharmaceutical company released the findings of its study of its orphan drug Pascomer, which it said found “statistically significant” benefits. However, it did not reach the threshold on the IGA scale – a five-point...

More Markets

NZ sharemarket enjoys good week with fourth gain
Markets Market close

NZ sharemarket enjoys good week with fourth gain

The S&P/NZX 50 Index closed at 11,938.08, up 64.04 points or 0.54%.

Graham Skellern 03 May 2024
BHP CEO flies to South Africa to push $65.4 billion takeover
Markets

BHP CEO flies to South Africa to push $65.4 billion takeover

The executives have already begun conversations with key stakeholders.

Bloomberg 03 May 2024
Rakon shareholder wants light shed on $400m bid
Markets

Rakon shareholder wants light shed on $400m bid

US giant Skyworks could be Rakon's new owner. One shareholder wants it to confirm.